Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Simultaneous RZV and aIIV4 Vaccination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05007041
Recruitment Status : Suspended (We will resume enrollment activities again for the 2022-2023 flu season.)
First Posted : August 16, 2021
Last Update Posted : June 7, 2022
Sponsor:
Collaborators:
Centers for Disease Control and Prevention
Johns Hopkins University
Information provided by (Responsible Party):
Duke University

Brief Summary:
The overall aim of the study is to compare the safety of simultaneous RZV (SHINGRIX®) and inactivated adjuvanted influenza vaccine aIIV4 (FLUAD®) versus simultaneous RZV (SHINGRIX®) and inactivated influenza HD-IIV4 (Fluzone® HD) vaccine in persons ≥65 years. A prospective, randomized, blinded clinical trial that will be conducted during the 2021/2022 and 2022/2023 influenza seasons. Over the course of these two influenza seasons, approximately 220 older adults will be enrolled at Duke University Medical Center, and 180 older adults at Johns Hopkins University Medical Center. Eligible subjects will be randomized to receive either simultaneous RZV/aIIV4 or RZV/HD-IIV4 vaccines. All subjects will be assessed for 7 days post-injection and safety and tolerability compared between the two groups. Serious adverse events and adverse events of clinical interest will be assessed 42 days post-vaccination and compared between the two groups. Health-related quality of life will be assessed pre-vaccination Day 1 through Day 8.

Condition or disease Intervention/treatment Phase
Pain Quality of Life Injection Site Reaction Adverse Drug Event Biological: FLUAD® Quadrivalent Biological: Fluzone® HD Quadrivalent Biological: SHINGRIX® Phase 4

Detailed Description:

Intention-to-Treat (ITT) Population: Defined as all subjects who are randomized and vaccinated.

Modified Intention-to-Treat (mITT) Population: Defined as all subjects who are randomized, vaccinated, and provide at least one day of complete data on the symptom diary.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Subjects, study coordinators, and investigators will be blinded to the type of flu vaccine administered in conjunction with the Shingrix vaccine.
Primary Purpose: Prevention
Official Title: Safety of Simultaneous Vaccination With Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Inactivated Influenza Vaccine (aIIV4)
Actual Study Start Date : September 21, 2021
Estimated Primary Completion Date : March 8, 2023
Estimated Study Completion Date : April 12, 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Shingles
MedlinePlus related topics: Flu Flu Shot Vaccines

Arm Intervention/treatment
Active Comparator: Recombinant Zoster Vaccine (RZV) and Quadrivalent adjuvanted influenza vaccine
In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the quadrivalent adjuvanted influenza vaccine (FLUAD® Quadrivalent) simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
Biological: FLUAD® Quadrivalent
Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Other Name: Influenza Vaccine, Adjuvanted (Quadrivalent)

Biological: SHINGRIX®
Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Other Name: Zoster vaccine recombinant, adjuvanted

Active Comparator: Recombinant Zoster Vaccine (RZV) and high-dose quadrivalent influenza vaccine
In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the (Fluzone® HD Quadrivalent) influenza vaccine simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
Biological: Fluzone® HD Quadrivalent
Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Other Name: High-dose quadrivalent influenza vaccine

Biological: SHINGRIX®
Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Other Name: Zoster vaccine recombinant, adjuvanted




Primary Outcome Measures :
  1. Number of participants with at least one severe (Grade 3) solicited local or systemic reactogenicity event after SHINGRIX® dose 1 in each study group [ Time Frame: Up to 8 days post-vaccination ]
    Modified Intention-to-Treat (mITT) Population


Secondary Outcome Measures :
  1. Number of participants with at least one severe (Grade 3) solicited local reactogenicity event after SHINGRIX® dose 1 in each study group [ Time Frame: Up to 8 days post-vaccination ]
    Modified Intention-to-Treat (mITT) Population

  2. Number of participants with at least one severe (Grade 3) solicited systemic reactogenicity after SHINGRIX® dose 1 in each study group [ Time Frame: Up to 8 days post-vaccination ]
    Modified Intention-to-Treat (ITT) Population

  3. Number of participants with at least one serious adverse event or adverse event of clinical interest after SHINGRIX® dose 1 in each study group [ Time Frame: Up 42 days post-vaccination ]
    Intention-to-Treat (ITT) Population



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female age ≥ 65 years
  2. Intention of receiving IIV and RZV based on ACIP-CDC guidelines
  3. Able to speak English
  4. Willing to provide written informed consent
  5. Living in the community
  6. Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls and clinic visits.
  7. If HIV positive, HIV should be clinically stable.

Exclusion Criteria:

  1. IIV or recombinant influenza vaccine (RIV) receipt during the respective 2021-2022 or 2022-2023 influenza season prior to study enrollment
  2. Prior receipt of recombinant zoster vaccine (SHINGRIX®)
  3. For non-COVID-19 Vaccines:

    • Receipt of any inactivated vaccine within 2 weeks prior to enrollment in this study
    • Receipt of any live vaccine within 4 weeks prior to enrollment in this study
    • Planning receipt of any non-COVID-19 vaccine during the entire period
  4. For COVID-19 Vaccines:

    • Receipt of COVID-19 vaccine within 2 weeks prior to enrollment in this study. For those who have initiated a COVID-19 vaccine series, enrollment is not allowed until 2 weeks after the final dose of a COVID-19 vaccine is completed.
    • Planning receipt of a COVID-19 vaccine within 2 weeks after administration of study influenza and first dose recombinant zoster study vaccines.
  5. Have acute illness or exacerbation of chronic illness within 72 hours of study vaccination
  6. Hospitalization within the last 30 days for any reason
  7. History of febrile illness (> 100.0°F or 37.8°C) within the past 24 hours prior to IIV administration
  8. Has immunosuppression as a result of an underlying illness or treatment, or use of chemotherapy or radiation therapy within the preceding 12 months
  9. Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) *Participants with a history of malignancy may be included if, after previous treatment by surgical excision, chemotherapy or radiation therapy, the participant has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure
  10. A history of autoimmune disease, that requires immunosuppressive agents or any other chronic medical condition considered clinically significant by the investigator
  11. Use of chronic oral or intravenous administration (≥14 days) of immunosuppressive doses of steroids, i.e., prednisone >10 mg per day, immunosuppressants or other immune-modifying drugs within 30 days of starting this study. (Use of topical, nasal, or inhaled steroids is permitted)
  12. Thrombocytopenia, bleeding disorder, or anticoagulant use contraindicating intramuscular injection (a daily aspirin may be acceptable)
  13. Contraindication to IIV receipt including history of severe allergic reaction after a previous dose of any influenza vaccine; or to a vaccine component, including egg protein
  14. Contraindication to RZV including history of a severe allergic reaction to any component of the RZV vaccine (including saponin or polysorbate 80) or to dose 2 of RZV
  15. History of Guillain-Barré syndrome
  16. History of Hepatitis C or active Hepatitis B
  17. Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study vaccination
  18. Dementia, any cognitive condition, or substance abuse that could interfere with study compliance
  19. Anyone who is already enrolled or plans to enroll in another clinical trial with an investigational product within 28 days of vaccine receipt. Co-enrollment in observational or behavioral intervention studies are allowed at any time while enrollment in a clinical trial involving an investigational product (other than vaccine) may occur after 28 days following vaccine receipt
  20. Any condition which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives
  21. Anyone who is a relative of any research study personnel
  22. Anyone who is an employee of any research study personnel

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05007041


Locations
Layout table for location information
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Centers for Disease Control and Prevention
Johns Hopkins University
Investigators
Layout table for investigator information
Principal Investigator: Kenneth Schmader, MD Duke University
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT05007041    
Other Study ID Numbers: Pro00108456
First Posted: August 16, 2021    Key Record Dates
Last Update Posted: June 7, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Duke University:
influenza vaccine
Shingrix vaccine
fever following vaccination
pain following vaccination
quality of life
Additional relevant MeSH terms:
Layout table for MeSH terms
Injection Site Reaction
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Extravasation of Diagnostic and Therapeutic Materials
Pathologic Processes
Vaccines
Immunologic Factors
Physiological Effects of Drugs